By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel is divided on the outcome of the lawsuit, but they agree that the real contest is in pipeline speed and manufacturing scale, not ad wording. The lawsuit may have PR implications and could lead to regulatory scrutiny of GLP-1 advertising.
Risk: Regulatory remedies, such as nationwide corrective ads or a temporary halt to comparative claims, could hit LLY’s marketing cadence and investor psychology.
Opportunity: Lilly's ability to scale manufacturing remains the true differentiator in the market.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
The GLP-1 market has been hot for a long time, but things are even more heated behind the scenes. Danish healthcare company Novo Nordisk (NYSE:NVO) and massive U.S. drugmaker Eli Lilly (NYSE:LLY) have been battling for supremacy in the massive U.S. GLP-1 market.
And as of Tuesday morning, the feud has officially landed in the courtroom, as Novo Nordisk announced it had filed a lawsuit against its rival in federal court.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Novo, the maker of GLP-1s Ozempic and Wegovy, claims that Eli Lilly’s ads for its competing GLP-1 brands, Mounjaro and Zepbound, rely on “deceptive advertising” that has caused “widespread confusion” in the marketplace.
The lawsuit demands that Lilly pull its “misleading comparative advertising across all platforms,” along with other demands.
Here’s what else the lawsuit is alleging and how it’s likely to impact both stocks.
Image source: Novo Nordisk.
Both Novo and Lilly are fighting tooth and nail to dominate the massive (and lucrative) U.S. GLP-1 market.
Novo Nordisk – which specializes in diabetes care – released its GLP-1 semaglutide in the U.S. under the Ozempic brand name in 2018 as a diabetes treatment. When it proved effective for weight loss, Novo began selling it as a weight-loss treatment under the Wegovy brand in 2021.
Meanwhile, Eli Lilly was developing a different GLP-1, tirzepatide, which it released as a type 2 diabetes treatment, Mounjaro, in 2022, and as a weight-loss treatment, Zepbound, in 2023.
Both companies’ stocks soared between 2018 and 2024 as the blockbuster potential of these weight-loss drugs became apparent. But in December 2024, a head-to-head clinical trial dubbed “SURMOUNT-5” showed that Lilly’s Zepbound provided superior weight loss to Novo’s Wegovy.
Since then, Lilly’s stock has risen 42.7% while Novo’s has dropped 53.8%. But the new lawsuit is putting that Surmount-5 head-to-head trial back in the spotlight.
Among other issues, Novo is objecting to Lilly’s use of data from the 2024 SURMOUNT-5 trial in its current advertising.
The SURMOUNT-5 trial found that patients taking a 10 mg or 15 mg dose of Zepbound lost an average of 20.2% of their body weight (about 50 pounds) after 72 weeks, while those taking a 1.7 mg or 2.4 mg dose of Wegovy only lost an average of 13.7% of their body weight (about 33 pounds) during the same time frame. The Wegovy doses were much smaller than the Zepbound doses because those were the maximum approved by the FDA at the time.
But this March, the FDA approved a 7.2 mg dose of Wegovy: three times higher than the 2.4 mg dose studied in the SURMOUNT-5 trial. In clinical tests, this higher dose of Wegovy resulted in average weight loss of 19% (about 47 pounds) after 72 weeks: practically identical to Zepbound’s SURMOUNT-5 performance.
Novo Nordisk calls this failure to account for the newer, higher dosage of Wegovy “a nationwide pattern of deceptive advertising which confuses consumers by using outdated studies.”
Eli Lilly, for its part, released a statement that it stands “firmly behind our advertising” and that it believes a head-to-head clinical trial is the “gold standard for comparing medicines.” The SURMOUNT-5 trial is the only study to date that has directly compared Wegovy and Zepbound.
Image source: The Motley Fool.
The U.S. GLP-1 market is expected to reach $100 billion by 2030, and Novo Nordisk and Eli Lilly are fiercely battling for supremacy.
Novo is asking the U.S. District Court for New Jersey – where it filed its suit – to issue a permanent injunction against the ads, order Lilly to issue corrective advertising, and award unspecified monetary damages.
I’m not an attorney, and there are still plenty of unclear details here, so I can’t predict the outcome. But given that the head-to-head comparison in Lilly’s ads was accurate until March, the potential monetary impact is likely minimal, especially considering Lilly has brought in $10.4 billion in free cash flow over the last 12 months.
Now, if the court rules that Lilly can no longer claim in future ads that Zepbound is more effective than Wegovy, that would be a win for Novo. With its huge resources, Eli Lilly would surely come up with an effective alternative ad campaign. But it might help Novo start to change the perception that Zepbound is the superior weight loss drug.
On the whole, though, this is unlikely to have a material impact on either stock.
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $364,562! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,247,668!
Now, it’s worth noting Stock Advisor’s total average return is 894% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of July 21, 2026. *
John Bromels has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly and Novo Nordisk. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"This suit is noise, not signal: the narrow weight-loss efficacy gap and ongoing supply shortages matter far more to 2030 market share than advertising wording."
The lawsuit is classic pharma trench warfare over comparative advertising in the $100B+ GLP-1 market. Novo (NVO) is right that Lilly's ads omit the newly approved 7.2 mg Wegovy dose, which delivered ~19% weight loss vs Zepbound's 20.2% in SURMOUNT-5—materially narrowing the gap. Yet Lilly's SURMOUNT-5 remains the only true head-to-head trial; courts rarely ban truthful historical data. Short-term NVO may see relief rally while LLY dips on optics, but neither faces material revenue hit given Lilly's $10.4B trailing FCF and both firms' supply constraints. The real contest remains pipeline speed and manufacturing scale, not ad wording.
If the court views Lilly's continued use of the outdated comparison as willful deception post-March approval, Novo could win broad injunctions plus damages that force Lilly to overhaul marketing and slow Zepbound momentum—especially if it triggers follow-on suits or FTC scrutiny, eroding LLY's 42.7% post-SURMOUNT-5 outperformance.
"The lawsuit is a lagging indicator of Novo Nordisk's failure to control the clinical narrative, reinforcing Eli Lilly's current position as the dominant market leader in the GLP-1 space."
This litigation is less about legal victory and more about a desperate attempt by Novo Nordisk (NVO) to arrest its momentum bleed. While the market views this as a minor legal spat, it signals that Novo is losing the 'mindshare' battle, which is critical in a consumer-facing drug market. Eli Lilly (LLY) is effectively using the SURMOUNT-5 data to cement a 'best-in-class' narrative that is becoming sticky with both patients and insurers. Even if the court forces a change in ad copy, the psychological anchor has been set. Investors should focus on the supply chain capacity; LLY’s ability to scale manufacturing remains the true differentiator, not the outcome of a Lanham Act false advertising claim.
If the court forces a nationwide retraction, the resulting 'corrective advertising' could ironically force the market to acknowledge that the higher dose of Wegovy is clinically equivalent, potentially triggering a sharp mean-reversion in NVO's valuation.
"This lawsuit is unlikely to move stock prices materially because Lilly's ads cite a valid trial, but it signals Novo's market-share loss is accelerating faster than the stock decline alone suggests."
The article frames this as a David-vs-Goliath PR battle, but the legal merits are weak for Novo. Lilly's SURMOUNT-5 ads cite a real head-to-head trial that was accurate when run; the 7.2mg Wegovy approval in March is new data, not retroactive truth. Courts rarely force corrective ads for studies that were valid at publication. The real risk isn't litigation—it's that Novo's lawsuit signals desperation as market share erodes (NVO down 53.8% YTD vs LLY up 42.7%). This could accelerate Novo's pivot away from weight loss, ceding the $100B market. Lilly's cash position ($10.4B FCF annually) makes damages immaterial.
If the court finds Lilly's continued use of outdated SURMOUNT-5 data constitutes ongoing deceptive practice post-March approval, an injunction could force Lilly to either run new head-to-head trials or remove comparative claims entirely—a material operational constraint in a market where efficacy perception drives adoption.
"Legal risk exists but is unlikely to derail the long-term GLP-1 growth story; remedies may be modest and marketing pivots will matter more than the ruling."
This lawsuit marks the marketing battleground in the $100B GLP-1 space. The strongest case against the obvious read is that the headline risk is more PR than P&L: even if Lilly is found liable for certain ads, remedies tend to be corrective statements rather than a revenue wipeout, and payer/provider dynamics will largely drive long-run growth. A real twist: the March FDA higher Wegovy dose narrows Zepbound's edge, and SURMOUNT-5 data are being partly superseded by newer Wegovy results, potentially decreasing the strategic leverage of a legal win. Still, the case highlights broader regulatory scrutiny of GLP-1 advertising that could temper marketing claims.
Even if Lilly faces some advertising remedies, the practical impact on sales could be muted because prescribers and patients rely on broader efficacy data and ongoing payer decisions; a ruling may be more symbolic than seller-shattering.
"Lilly's ongoing use of outdated head-to-head data creates material legal and marketing risk that Gemini underweights."
Gemini's 'mindshare' narrative ignores that SURMOUNT-5's 20.2% vs 15.7% edge is now factually stale post-7.2mg approval showing 19%. Continued use risks Lanham Act violation and FTC referral. This isn't mere optics; a preliminary injunction could halt comparative campaigns for months, forcing Lilly to spend on new trials while Novo regains narrative control in a supply-constrained duopoly.
"The Lanham Act threshold for false advertising is higher than mere clinical nuance, making Novo's legal path unlikely to yield a material injunction."
Grok, you're overestimating the legal impact of the 7.2mg approval. Lanham Act claims require proving the ad is literally false or misleading to the consumer. Since SURMOUNT-5 remains the only peer-reviewed head-to-head trial, Lilly’s claims are technically accurate based on the study’s data. Courts won't mandate an injunction based on a 'narrowing gap' from a different trial. This is a distraction; the real risk is that Novo is burning cash on legal fees while supply-chain execution remains the only metric that matters.
"Material omission of newer efficacy data can trigger FTC action even if the cited study remains technically accurate."
Gemini conflates 'technically accurate' with 'not misleading.' Lilly's continued SURMOUNT-5 ads post-March, when 7.2mg Wegovy data exist showing 19% weight loss, may trigger FTC scrutiny under 'material omission' doctrine—not just false claims. Courts have enjoined ads citing outdated comparisons when newer superior data are available and knowingly withheld. Grok's FTC referral risk is real; Gemini underweights regulatory, not just litigation, exposure.
"Regulatory remedies for post-March data could dwarf supply constraints and create meaningful near-term downside to LLY's 'best-in-class' narrative."
Gemini downplays legal risk, but the real swing factor isn't cash burn—it's regulatory remedies. If a court or FTC flags material omission post-March data, we could see nationwide corrective ads, disclaimers, or even a temporary halt to comparative claims, lasting months. That would hit LLY’s marketing cadence and investor psychology far more than supply constraints. The market should price in a non-trivial near-term risk to LLY's narrative, not just long-run growth.
The panel is divided on the outcome of the lawsuit, but they agree that the real contest is in pipeline speed and manufacturing scale, not ad wording. The lawsuit may have PR implications and could lead to regulatory scrutiny of GLP-1 advertising.
Lilly's ability to scale manufacturing remains the true differentiator in the market.
Regulatory remedies, such as nationwide corrective ads or a temporary halt to comparative claims, could hit LLY’s marketing cadence and investor psychology.